HRP20110349T1 - Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma - Google Patents
Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma Download PDFInfo
- Publication number
- HRP20110349T1 HRP20110349T1 HR20110349T HRP20110349T HRP20110349T1 HR P20110349 T1 HRP20110349 T1 HR P20110349T1 HR 20110349 T HR20110349 T HR 20110349T HR P20110349 T HRP20110349 T HR P20110349T HR P20110349 T1 HRP20110349 T1 HR P20110349T1
- Authority
- HR
- Croatia
- Prior art keywords
- sulfonamide compound
- cancer
- treatment
- substance
- inhibitory effect
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title claims abstract 12
- -1 sulfonamide compound Chemical class 0.000 title claims abstract 12
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 title claims 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract 11
- 239000000126 substance Substances 0.000 claims abstract 11
- LWGUASZLXHYWIV-UHFFFAOYSA-N 3-cyano-n-(3-cyano-4-methyl-1h-indol-7-yl)benzenesulfonamide Chemical compound C1=2NC=C(C#N)C=2C(C)=CC=C1NS(=O)(=O)C1=CC=CC(C#N)=C1 LWGUASZLXHYWIV-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract 2
- 229960005395 cetuximab Drugs 0.000 claims abstract 2
- 229960001433 erlotinib Drugs 0.000 claims abstract 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002584 gefitinib Drugs 0.000 claims abstract 2
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005054111 | 2005-02-28 | ||
| PCT/JP2006/304218 WO2006090930A1 (ja) | 2005-02-28 | 2006-02-28 | スルホンアミド化合物の新規併用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110349T1 true HRP20110349T1 (hr) | 2011-07-31 |
Family
ID=36927547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110349T HRP20110349T1 (hr) | 2005-02-28 | 2011-05-11 | Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090047278A1 (ja) |
| EP (1) | EP1859793B1 (ja) |
| JP (1) | JPWO2006090930A1 (ja) |
| KR (1) | KR20070108270A (ja) |
| CN (1) | CN101163468A (ja) |
| AU (1) | AU2006217692A1 (ja) |
| CA (1) | CA2599115A1 (ja) |
| CY (1) | CY1111579T1 (ja) |
| DE (1) | DE602006021401D1 (ja) |
| DK (1) | DK1859793T3 (ja) |
| ES (1) | ES2362898T3 (ja) |
| HR (1) | HRP20110349T1 (ja) |
| ME (1) | ME01222B (ja) |
| PL (1) | PL1859793T3 (ja) |
| PT (1) | PT1859793E (ja) |
| RS (1) | RS51821B (ja) |
| SI (1) | SI1859793T1 (ja) |
| WO (1) | WO2006090930A1 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60134679D1 (de) * | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
| US7994159B2 (en) * | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| US20100150884A1 (en) * | 2005-02-10 | 2010-06-17 | Oncolys Biopharma Inc. | Anticancer Agent to Be Combined with Telomelysin |
| US20090047365A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| CA2620594C (en) * | 2005-09-01 | 2012-08-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition having improved disintegratability |
| WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| ES2556173T3 (es) * | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CN101616671A (zh) * | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| EP2119707B1 (en) * | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
| EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
| RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| US11807606B2 (en) | 2018-01-25 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Sulfonamide derivatives for protein degradation |
| CA3098428A1 (en) | 2018-04-18 | 2019-10-24 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2021151974A1 (en) | 2020-01-28 | 2021-08-05 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Interfering with mrna splicing to enhance response to checkpoint immunotherapies. |
| EP4149483A2 (en) * | 2020-05-15 | 2023-03-22 | Fred Hutchinson Cancer Center | Compositions and methods for enhancing cancer immunotherapy |
| CN113679720A (zh) * | 2020-05-19 | 2021-11-23 | 江苏苏中药业集团股份有限公司 | 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| JPS5857710A (ja) | 1981-09-30 | 1983-04-06 | Matsushita Electric Works Ltd | コイル |
| DE3474040D1 (en) * | 1984-11-22 | 1988-10-20 | Holsten Brauerei Ag | Beer and process for its preparation |
| IL80032A (en) * | 1985-09-23 | 1992-07-15 | Lilly Co Eli | Anti-tumor phenyl-aminocarbonylsulfonamides,their preparation and pharmaceutical compositions containing them |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| ATE255106T1 (de) * | 1993-09-10 | 2003-12-15 | Eisai Co Ltd | Bicyclische, heterocyclische sulfonamide und sulfonsäureester |
| DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| RS49836B (sr) * | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| EP1296714B1 (en) * | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
| DK1401806T3 (da) * | 2001-06-06 | 2006-11-27 | Lilly Co Eli | Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler |
| DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
| TWI281916B (en) | 2001-10-25 | 2007-06-01 | Lilly Co Eli | Antitumor compounds and methods |
| AU2003211594A1 (en) * | 2002-03-05 | 2003-09-16 | Eisai Co., Ltd. | Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor |
| US7151104B2 (en) * | 2002-09-19 | 2006-12-19 | Schering Corporation | Pyrazolopyridines as cyclin dependent kinase inhibitors |
| JP3785390B2 (ja) | 2002-09-24 | 2006-06-14 | 平野整機工業株式会社 | 自転車後輪駆動装置及び自転車 |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| WO2006030947A1 (ja) * | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
-
2006
- 2006-02-28 JP JP2007504857A patent/JPWO2006090930A1/ja active Pending
- 2006-02-28 DE DE602006021401T patent/DE602006021401D1/de active Active
- 2006-02-28 ES ES06715261T patent/ES2362898T3/es active Active
- 2006-02-28 RS RS20110308A patent/RS51821B/en unknown
- 2006-02-28 ME MEP-2011-128A patent/ME01222B/me unknown
- 2006-02-28 CN CNA2006800137614A patent/CN101163468A/zh active Pending
- 2006-02-28 US US11/885,081 patent/US20090047278A1/en not_active Abandoned
- 2006-02-28 SI SI200631061T patent/SI1859793T1/sl unknown
- 2006-02-28 CA CA002599115A patent/CA2599115A1/en not_active Abandoned
- 2006-02-28 PL PL06715261T patent/PL1859793T3/pl unknown
- 2006-02-28 DK DK06715261.1T patent/DK1859793T3/da active
- 2006-02-28 PT PT06715261T patent/PT1859793E/pt unknown
- 2006-02-28 AU AU2006217692A patent/AU2006217692A1/en not_active Abandoned
- 2006-02-28 EP EP06715261A patent/EP1859793B1/en active Active
- 2006-02-28 KR KR1020077022300A patent/KR20070108270A/ko not_active Application Discontinuation
- 2006-02-28 WO PCT/JP2006/304218 patent/WO2006090930A1/ja active Application Filing
-
2011
- 2011-05-11 HR HR20110349T patent/HRP20110349T1/hr unknown
- 2011-06-17 CY CY20111100583T patent/CY1111579T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2362898T3 (es) | 2011-07-14 |
| SI1859793T1 (sl) | 2011-08-31 |
| JPWO2006090930A1 (ja) | 2008-07-24 |
| ME01222B (me) | 2013-06-20 |
| EP1859793A4 (en) | 2008-07-23 |
| RS51821B (en) | 2012-02-29 |
| EP1859793A1 (en) | 2007-11-28 |
| WO2006090930A1 (ja) | 2006-08-31 |
| CY1111579T1 (el) | 2015-10-07 |
| PT1859793E (pt) | 2011-07-05 |
| AU2006217692A1 (en) | 2006-08-31 |
| US20090047278A1 (en) | 2009-02-19 |
| DK1859793T3 (da) | 2011-08-01 |
| CN101163468A (zh) | 2008-04-16 |
| DE602006021401D1 (de) | 2011-06-01 |
| CA2599115A1 (en) | 2006-08-31 |
| EP1859793B1 (en) | 2011-04-20 |
| PL1859793T3 (pl) | 2011-09-30 |
| KR20070108270A (ko) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110349T1 (hr) | Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| BRPI0511933B8 (pt) | derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica | |
| HN2002000319A (es) | Benzamida, heteroarilamida y amidas inversas | |
| UY27619A1 (es) | Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico | |
| BRPI0514372A (pt) | inibidores de tiazol de frutose 1, 6-bisfosfatase | |
| BRPI0606112B8 (pt) | 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos | |
| EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
| ECSP077271A (es) | Derivados de pirimidina | |
| BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
| BRPI0507653A (pt) | derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso | |
| ECSP077259A (es) | Derivados de pirimidina | |
| BRPI0513901A (pt) | derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| BRPI0508464B8 (pt) | sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| UY30048A1 (es) | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| DK2041133T3 (da) | Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik | |
| BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição | |
| SE0403171D0 (sv) | New compounds | |
| ECSP066324A (es) | Derivados de 6-indolilsulfonamidas, su preparación y su uso como moduladores de 5-ht-6. | |
| UY29892A1 (es) | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones |